Multicenter, Open-Label Efficacy and Safety Study of Oral Budesonide-MMX 9mg Extended Release Tablets in Patients With Mild to Moderate, Active Ulcerative Colitis
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 61
- 试验地点
- 15
- 主要终点
- The Percentage of Patients Achieving Clinical Remission
研究概览
简要总结
Open-label, 8 week study, to assess the efficacy and safety of oral Budesonide-MMX 9 mg Extended-release Tablets in patients with mild to moderate, active ulcerative colitis who are not in remission based on the Ulcerative Colitis Disease Activity Index in study CB-01-02/01 (parent study [NCT00679432]).
详细描述
Patients who complete the parent study and who do not achieve clinical remission will be eligible to receive 8 weeks of open-label treatment with Budesonide-MMX 9mg if they satisfy the entry criteria for this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients 18 to 74 years of age, who are able to understand and voluntarily provide written informed consent
- •Completed all Final Visit assessments for study CB-01-02/01 (NCT00679432) and are not in clinical remission
- •Diagnosis of ulcerative colitis of mild to moderate severity with an Ulcerative Colitis Disease Activity Index (UCDAI) <or= 10 according to Sutherland
- •Females of child-bearing potential must have had a serum pregnancy test performed at the Final Visit of the parent study, and must use an acceptable contraceptive method throughout the treatment period. Female subjects must also not be actively breast-feeding through the entire study period.
- •Ability to comprehend the full nature and purpose of the study, including possible risks and side effects
- •Ability to co-operate with the investigator and to comply with the requirements of the entire study
排除标准
- •Did not complete study CB-01-02/01
- •Achieved clinical remission in study CB-01-02/01
- •Patients with severe ulcerative colitis (UCDAI >10)
- •Patients with infectious colitis
- •Evidence or history of toxic megacolon
- •Severe anemia, leucopenia, or granulocytopenia
- •Use of immunosuppressive agents in the last 8 weeks before the study
- •use of anti-tumor necrosis factor alpha agents in the last three months
- •Concomitant use of any rectal preparation for the treatment of ulcerative colitis
- •Concomitant use of antibiotics
- •Concurrent use of cytochrome P-450 3A4 (CYP3A4) inducers and CYP3A4 inhibitors.
- •Patients with verified, presumed of expected pregnancy or ongoing lactation
- •Patients with liver cirrhosis, or evident hepatic or renal disease or insufficiency and/or severe impairment of the bio-humoral parameters (i.e., 2x upper limit of normal for alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, or creatinine)
- •Patients with severe disease(s) in other organs of systems
- •Patients with local of systemic complications of other pathological states requiring a therapy with corticosteroids and/or immunosuppressive agents
- •Patients diagnosed with Type 1 diabetes
- •Patients diagnosed with or with a family history of glaucoma
- •Patients with known hepatitis B, hepatitis C, or with human immunodeficiency virus (HIV), according to the local privacy policy
- •Any other medical condition that in the principal investigator's opinion would make the administration of the study drug or study procedures hazardous to the subject or obscure the interpretation of adverse events
研究组 & 干预措施
Budesonide
Budesonide-MMX 9 mg tablet
干预措施: Budesonide (Drug)
结局指标
主要结局
The Percentage of Patients Achieving Clinical Remission
时间窗: At the end of the 8 week treatment period
The primary efficacy endpoint is clinical remission at 8 weeks, defined as a Ulcerative Colitis Disease Activity Index score of \< or = 1 with a score of 0 for both rectal bleeding and stool frequency, and \> or = 1 point reduction from baseline in endoscopy score, without any sign of mucosal friability (a score of 0 for mucosal appearance). The UCDAI has 4 components. Each component is scored on scale of 0 to 3 (total maximum \[worst\] score = 12). Definitions of component scores are as follows: stool frequency: 0 = normal frequency, 1 = 1 - 2 stools per day greater than normal frequency, 2 = 3 - 4 stools per day greater than normal frequency, and 3 = \> 4 stools per day greater than normal frequency; rectal bleeding: 0 = none, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood; physician's rating of disease activity: 0 = normal, 1 = mild, 2 = moderate, 3 = severe; mucosal appearance: 0 = normal, 1 = mild friability, 2 = moderate friability, 3 = exudation, spontaneous bleeding.
次要结局
- The Secondary Efficacy Endpoint is Clinical Improvement(After 8 weeks treatment period)
- Endoscopic Improvement(8 weeks)
- Safety Evaluations: the Numbers of Patients Who Experience Serious Adverse Events (SAEs) or Other Nonserious Adverse Events (AEs) During the Course of the Study.(Throughout the 8 week treatment period)